Background-To test formally the inflammatory hypothesis of atherothrombosis, an agent is needed that reduces inflammatory biomarkers such as C-reactive protein, interleukin-6, and fibrinogen but that does not have major effects on lipid pathways associated with disease progression. Methods and Results-We conducted a double-blind, multinational phase IIb trial of 556 men and women with well-controlled diabetes mellitus and high cardiovascular risk who were randomly allocated to subcutaneous placebo or to subcutaneous canakinumab at doses of 5, 15, 50, or 150 mg monthly and followed over 4 months. Compared with placebo, canakinumab had modest but nonsignificant effects on the change in hemoglobin A1c, glucose, and insulin levels. No effects were seen for low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, or non-high-density lipoprotein cholesterol, although triglyceride levels increased Ϸ10% in the 50-mg (Pϭ0.02) and 150-mg (Pϭ0.03) groups. By contrast, the median reductions in C-reactive protein at 4 months were 36.4%, 53.0%, 64.6%, and 58.7% for the 5-, 15-, 50-, and 150-mg canakinumab doses, respectively, compared with 4.7% for placebo (all P values Յ0.02). Similarly, the median reductions in interleukin-6 at 4 months across the canakinumab dose range tested were 23.9%, 32.5%, 47.9%, and 44.5%, respectively, compared with 2.9% for placebo (all PՅ0.008), and the median reductions in fibrinogen at 4 months were 4.9%, 11.7%, 18.5%, and 14.8%, respectively, compared with 0.4% for placebo (all P values Յ0.0001). Effects were observed in women and men. Clinical adverse events were similar in the canakinumab and placebo groups. Conclusions-Canakinumab, a human monoclonal antibody that neutralizes interleukin-1␤, significantly reduces inflammation without major effect on low-density lipoprotein cholesterol or high-density lipoprotein cholesterol. These phase II trial data support the use of canakinumab as a potential therapeutic method to test directly the inflammatory hypothesis of atherosclerosis. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00900146. ; and Klinikum Hanover Nordstadt, Hannover, Germany (J.H.).
A therosclerosis is an inflammatory disease, 1 and biomarkers of inflammation, such as C-reactive protein (CRP), 2 interleukin-6 (IL-6), 3 and fibrinogen 4 associate consistently with an increased risk of future cardiovascular events. In the Emerging Risk Factors Collaboration, each standard deviation increase in CRP is associated with an increase in vascular risk at least as large as that associated with an SD increase in either blood pressure or cholesterol. 5 Furthermore, in multiple statin trials, on-treatment levels of CRP have predicted drug efficacy as accurately as on-treatment levels of low-density lipoprotein cholesterol (LDL-C). 6 -10 However, despite these clinical data and broad scientific interest in inflammation as a fundamental determinant of atherosclerotic disease, no large-scale outcome trial to date has specifically targeted inflammation as a method to reduce cardiovascular event rates. The optimal agent for such a trial would be one that reduces inflammatory biomarkers, such as CRP, IL-6, and fibrinogen, but that has minimal effects on LDL-C or high-density lipoprotein cholesterol (HDL-C).
Clinical Perspective on p 2748
One promising anti-inflammatory approach with potential relevance for cardiovascular disease is inhibition of the proinflammatory cytokine interleukin-1 (IL-1), particularly the IL-1␤ isoform that is secreted and acts locally but that also induces systemic effects. Animal studies suggest that exposure to IL-1 promotes atherogenesis, whereas loss of IL-1 function associates with reduced atherosclerotic lesions. 11, 12 Human coronary atheromata contain IL-1␤ mRNA and protein, 13 and human plaques overexpress caspase-1 (IL-1␤ converting enzyme) that activates pro-IL-1␤ to its active form. 14 Recently , investigators showed that cholesterol crystals activate the NOD-like receptor pyrin domaincontaining protein inflammasome, the supramolecular complex that contains and regulates caspase-1, which is critical for the production of active IL-1␤. 15 Thus, cholesterol itself may serve as an endogenous danger signal triggering IL-1␤ production and a systemic proinflammatory response. 15 Based in part on these data, we and other clinical investigators have hypothesized that inhibition of IL-1␤ might reduce vascular event rates among individuals with coronary disease or diabetes mellitus. One agent under evaluation is canakinumab, a monoclonal antihuman IL-1␤ antibody approved for the treatment of rare hereditary IL-1␤-driven disorders, such as Muckle-Wells syndrome and other cryopyrin-associated periodic syndromes. 16 Canakinumab binds to human IL-1␤, blocking interaction of this cytokine with its receptors, an effect that should in turn reduce circulating levels of IL-6 and hepatic production of the acute-phase reactants CRP and fibrinogen. To date, however, clinical data demonstrating the magnitude and consistency of these effects in stable but high-risk patients at risk for future cardiovascular events have been sparse.
As part of the canakinumab development program, a multinational phase IIb randomized, placebo-controlled trial was conducted to evaluate the effects of this agent on hemoglobin A1c (HbA1c), glucose, lipids, CRP, IL-6, and fibrinogen among men and women with diabetes mellitus and high cardiovascular risk. This report presents the results of that phase IIb study and its implications for a large-scale cardiovascular outcomes trial using canakinumab to directly test the inflammatory hypothesis of atherothrombosis.
Methods
A phase IIb parallel-group, randomized, placebo-controlled trial evaluating monthly canakinumab was conducted at 108 centers in 14 countries (Argentina, Belgium, Germany, Great Britain, Hong Kong, Hungary, India, Japan, Peru, Romania, South Africa, Korea, Turkey, and the United States). The study protocol was approved by the independent ethics committee of the institutional review board for each center.
Patients aged 18 to 74 years with type 2 diabetes mellitus as defined by World Health Organization criteria (either a fasting plasma glucose Ն7.0 mmol/L or an oral glucose tolerance test 2-hour plasma glucose Ն11.1 mmol/L before screening) were eligible to participate if they also satisfied any 1 of the following criteria sets: (1) were naive to oral antidiabetes drug therapy, had an HbA1c of 7.5% to 11.0%, and were eligible for metformin monotherapy; (2) were already on stable met-formin monotherapy for Ն3 months at screening, had an HbA1c of 7% to 9%, and were taking metformin as their only oral antidiabetes therapy; or (3) were taking an ␣-glucosidase inhibitor, had that agent washed out for Ն1 week before run-in, had an HbA1c of 7% to 9%, and were eligible for metformin therapy. 17 In addition, at 1 month before randomization, subjects were required to have a morning fasting plasma glucose Ͻ10.0 mmol/L and to be on a daily dose of metformin Ն1000 mg daily. Exclusion criteria included type 1 diabetes mellitus or the presence of a relative contraindication for IL-1␤ inhibition including risk factors for tuberculosis, active or recurrent hepatitis B or C, chronic infections associated with an immunocompromised condition, or the use of other immune-modulating agents. Other exclusion criteria included a history of cancer or recent cardiovascular event, a requirement for live vaccinations during or immediately preceding the trial, and women who were pregnant, nursing, or unable to use effective contraception. Trial recruitment began in April 2009 and was completed in November 2010.
After an 8-week open-label placebo run-in period, all of the trial participants were randomized to 1 of 4 active treatment groups (SC canakinumab at 5, 15, 50, or 150 mg monthly) or to SC placebo monthly. This dosing range spanned a 30-fold difference and was chosen on the basis of pilot work in diabetic patients to increase the likelihood of a dose-response curve with Ն2 doses at near maximal effect on HbA1c; the highest dose of 150 mg monthly was selected on the basis of data from rare inflammatory syndromes of IL-1␤ overproduction where this dose showed convincing efficacy for preventing disease activity flares. Randomization into these groups was done in a 1:1:1:1:2 ratio, stratified by previous diabetes mellitus medication group and by country. All of the participants were then followed over a 4-month treatment period. For the current analysis, fasting pre-enrollment plasma samples and fasting plasma samples after 4 months of treatment were assayed in a central core laboratory for HbA1c, glucose, insulin levels, LDL-C, HDL-C, triglycerides, high-sensitivity CRP, IL-6, and fibrinogen using standard assay techniques. Safety evaluations occurred at all of the study visits, and adverse events were recorded throughout the study period.
Statistical Analyses
On a prespecified basis as outlined in the trial statistical analysis plan, to address the effect of monthly canakinumab or placebo, the change in each measured parameter was computed over the 4-month trial period. Per protocol, for HbA1c, glucose, insulin, and homeostatic model of assessment of insulin resistance, data were excluded for those who used glucose-lowering medications other than metformin during the trial, and P values addressing change in HbA1c on an absolute scale were adjusted for multiple comparisons. For all of the measured biomarkers, an ANCOVA was used for the comparison of each active dose versus placebo. The ANCOVA model included treatment and metformin dose category as the classification variables and baseline levels of each measured plasma marker as the covariate. The last observation carried forward was used for patients without a 4-month sample for any reason; laboratory evaluations were incomplete for Ն1 of the study variables in 7.2% of the study population at 4 months and, thus, was the last value was carried forward in these instances. For the inflammatory biomarkers that have skewed distributions, data were log transformed. As an example, for CRP, P values for the total group were calculated from an ANCOVA of the change from baseline in log CRP with treatment and metformin dose group as main effects and baseline CRP as a covariate; P values for the post hoc sex-stratified groups were calculated from an ANCOVA of the change from baseline in log CRP with treatment and metformin dose group as main effects and baseline CRP and sex as covariates including interaction terms treatment*gender, treatment*baseline CRP, and gender*baseline CRP. Additional post hoc sensitivity analyses stratified by baseline CRP level (above or below 2 mg/L) and by baseline statin use were also performed.
Role of the Funding Source
The sponsor of the study collected the trial data and monitored the study sites, and in collaboration with the academic investigators designed the study analysis plan for this manuscript. Statistical analyses were conducted initially by the study sponsor but subsequently validated by a fully independent academic study statistician.
Results

Baseline Characteristics
The flow of patients included in the trial is summarized in Figure  1 . Of 556 patients randomized, 551 received Ն1 dose of canakinuamb and, thus, composed the evaluable cohort. As anticipated in a randomized trial setting, clinical and demographic characteristics of the study population were similar in the randomized study groups 17 All of the measured blood parameters are shown as median values. IL indicates interleukin; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model of assessment of insulin resistance; and HbA1c, hemoglobin A1c. and the mean duration of type 2 diabetes mellitus was 3.7 years. These diabetics had well-controlled glucose levels on metformin therapy, as indicated by baseline HbA1c of 7.4%. The proportions of individuals randomized from the Americas, Europe, and Africa/Asia were 27.2%, 27.4%, and 45.4%, respectively.
Effects of Canakinumab on HbA1c, Glucose, Insulin, and Lipids
In this study population of diabetic patients with wellcontrolled HbA1c, there was a modest but nonsignificant effect of canakinumab on the change in HbA1c at 4 months, although the 5-mg dose lowered HbA1c less than the 15-, 50-, and 150-mg doses. After adjusting for multiple comparisons, however, no dose of canakinumab differed significantly from placebo at the Ͻ0.05 significance level for the change in HbA1c at study completion (Table 2) . Similarly, among these individuals with relatively well-controlled diabetes mellitus at baseline, there were no statistically significant effects of canakinumab on the change in plasma glucose, fasting insulin, or in calculated values for the change in homeostatic model of assessment of insulin resistance at 4 months 15 ( Table 2) .
As compared with placebo, canakinumab lacked consistent effect on the change in LDL-C, HDL-C, or non-HDL-C over the study period ( Table 2 ). Median triglyceride levels did rise Ϸ10.0% at 4 months as compared with a 2.5% increase among those allocated to placebo, an effect that was significant for the 50-mg (Pϭ0.02) and 150-mg (Pϭ0.03) doses.
Effects of Canakinumab on CRP, IL-6, and Fibrinogen
Compared with placebo, statistically significant reductions in CRP, IL-6, and fibrinogen were observed after canakinumab injection and maintained throughout the study period. Tables 3 through 5 present the median levels of CRP, IL-6, and fibrinogen at baseline and at 4 months, according to randomized study group. As shown in Table 3 , the median reductions in CRP at 4 months were 36.4%, 53.0%, 64.6%, and 58.7% for the 5-, 15-, 50-, and 150-mg canakinumab doses, respectively, compared with 4.7% for placebo (all P values Յ0.02).
Similarly, and as shown in Table 4 , the median reductions in IL-6 at 4 months across the canakinumab dose range tested were 23.9%, 32.5%, 47.9%, and 44.5%, respectively, compared with 2.9% for placebo (all PՅ0.008). Finally, as shown in Table 5 , the median reductions in fibrinogen at 4 months were 4.9%, 11.7%, 18.5%, and 14.8%, respectively, compared with 0.4% for placebo (all P values Յ0.0001). As shown in sex-stratified analyses (Tables 3-5 ), these antiinflammatory effects were present for women as well as men.
The dose-response effects of canakinumab on CRP, IL-6, and fibrinogen in placebo-subtracted analyses are shown in Figure 2 . The effect of canakinumab on reductions in CRP, IL-6, and fibrinogen were similar in magnitude among all of the ethnic groups studied. However, despite the diversity of our study population, the power to detect a small difference between groups is limited.
Safety Monitoring
Adverse events associated with canakinumab were infrequent and generally had rates similar to that of placebo. Table 6 presents treatment-emergent adverse events during the randomized 4-month intervention period. Treatment-emergent adverse events leading to permanent discontinuation of randomized therapy during the 4-month trial period occurred in 2 participants allocated to canakinumab and 1 allocated to placebo. There was 1 injection site reaction during the 4-month trial period among those allocated to canakinumab and 2 among those allocated to placebo.
IL-1␤ blockade is expected to lower the white blood cell count attributed to a reduction in neutrophil count, 16 and this previous observation was confirmed in our study. Specifically, 39 (10.7%) of 366 canakinumab-treated patients and 8 (4.6%) of 175 placebo-treated patients had some neutropenia during the trial or during its extension phase, defined as an absolute neutrophil count Ͻ1500/mm. When examining low postbaseline neutrophils, 2 of 541 patients (1 canakinumab 15-mg treated and 1 placebo treated) achieved Common Terminology Criteria for Adverse Events grade 3 neutropenia (defined as absolute neutrophil count Ͻ1000/mm), and no patients in any treatment group experienced Common Terminology Criteria for Adverse Events grade 4 neutropenia (an event considered to have life-threatening consequences or need for intervention). No other systematic differences in blood counts were noted.
Sensitivity Analyses
On a post hoc basis, we performed 2 additional sensitivity analyses. First, we addressed the impact of canakinumab separately among those with baseline CRP levels above or below 2 mg/L, a commonly used cut point for CRP in clinical practice. As anticipated, percentage reductions in CRP were greater in magnitude among those with higher baseline levels (median percentage reductions were 52%, 66%, 69%, and 72% for those with CRP levels Ͼ2 mg/L in the 5-, 15-, 50-, and 150-mg canakinumab groups respectively), but significant effects versus placebo were also seen for those with baseline CRP values Յ2 mg/L for the 15-, 50-, and 150-mg canakinumab groups (median percentage reductions, 31%, 55%, and 27%, respectively). Table  SI , available in the online-only Data Supplement, presents similar data for the effects of canakinumab on IL-6 and fibrinogen for those with baseline CRP values above or below 2 mg/L. Second, we addressed the impact of previous use of statin therapy on these findings. In this analysis, effects remained significant in the subgroup of study participants taking statin therapy. For example, among statin users, the median percentage reductions in CRP were 54%, 45%, 71%, and 54% in the 5-, 15-, 50-, and 150-mg canakinumab groups as compared with 6% among those on placebo (all P values Յ0.02). Similar effects were observed when sensitivity analyses stratified by statin use were performed for the percentage of change in IL-6 and fibrinogen.
Discussion
Whether inhibition of inflammation will reduce cardiovascular events is currently a major and unresolved issue in clinical care. Much of the data evaluating the impact of atherosclerotic therapies on inflammatory biomarkers and clinical end points has derived from randomized trials of aspirin or statins, agents that not only reduce inflammation but that either inhibit platelet function or significantly lower LDL-C. In particular, multiple statin trials indicate that reductions in CRP and reductions in LDL-C contribute to clinical efficacy, 6 -10 and recent genetic data indicate that these effects are at least partly independent of each other. 18, 19 Although hypothesis generating, existing analyses of inflammatory biomarkers within statin trials cannot definitively evaluate whether lowering inflammation alone will lower vascular risk because of the ability of the statin to affect both inflammation and lipid levels. Similarly, the observation that aspirin reduces vascular risk in primary prevention with a greater magnitude when CRP levels are high 20 does not definitively address this issue, because aspirin acts as an effective antithrombotic agent. Nonetheless, these observations, as well as the rapid growth in our understanding of the role played by inflammation in atherothrombosis, 1,21 provide the scientific basis for proceeding with a series of cardiovascular inflammation reduction trials designed to test directly whether anti-inflammatory agents without major confounding effects on other atherosclerotic pathways can reduce cardiovascular event rates. 22 In this phase IIb randomized trial, monthly doses of canakinumab, a monoclonal antihuman IL-1␤ antibody, had a modest but nonsignificant effect on HbA1c and glucose with no effect on LDLC, HDL-C, or non-HDL-C among well-controlled (HbA1c baseline 7.4%) diabetic patients at high risk for cardiovascular disease. Yet, in this same study population, canakinumab was highly effective at reducing CRP, IL-6, and fibrinogen levels. These effects were similar among men and women and dose dependent for all 3 inflammatory biomarkers. The largest effects were observed for CRP where median reductions were Ͼ50% at canakinumab doses Ͼ15 mg monthly. Thus, these phase IIb data indicate that canakinumab provides a therapeutic method to test directly the inflammatory hypothesis of atherosclerosis without major confounding effects on LDL-C or HDL-C. It is important to note, however, that an Ϸ10% increase in triglycerides was observed for the 2 highest doses of canakinumab.
Because healthy individuals have low or undetectable circulating levels of IL-1␤ in plasma and canakinumab leads to the formation of IL-1␤ antibody complexes that can be measured but that are biologically inactive and thus uninformative, we did not investigate serial plasma levels of IL-1␤ directly in this trial. Rather, as typically is done in clinical translational studies of agents such as canakinumab, we sought evidence of a downstream anti-inflammatory effect on the messenger cytokine IL-6 and on consequent changes in classic acute-phase reactants, such as CRP and fibrinogen. We recognize that fibrinogen has potential dual roles as both an acute-phase reactant and as a mediator of coagulation and thus that additional benefits on thrombosis may result from anti-inflammatory therapy with agents such as canakinumab.
In addition to its randomized, placebo-controlled design, a major strength of our trial is that it directly addresses the role of canakinumab in a human population, thus avoiding controversy regarding whether observations of IL-1 inhibition made in animals have relevance for patients with or at risk for cardiovascular disease. 23, 24 Furthermore, by focusing our evaluation on a group of well-controlled diabetics whose treatment was limited to metformin monotherapy, we avoided several additional sources of confounding that can occur in studies of inflammatory biomarkers in high-risk diabetic patients with and without vascular disease. 25, 26 Our trial was also well powered to demonstrate clinically relevant changes in all of the study parameters.
Despite these strengths, limitations of our trial merit consideration. First, although the numbers of adverse events Units for CRP are milligrams per liter. The last observation carried forward was used for patients without a 4-mo sample for any reason. P values for the total group are calculated from an ANCOVA of the change from baseline in log CRP with treatment and metformin dose group as main effects and baseline CRP as a covariate. P values for the sex-stratified groups are calculated from an ANCOVA of the change from baseline in log CRP with treatment and metformin dose group as main effects and baseline CRP and sex as covariates including interaction terms treatment*gender, treatment*baseline CRP, and gender*baseline CRP. IQR indicates interquartile range; CRP, C-reactive protein.
reported in our data are not substantively different from placebo, the length of intervention in this dose-finding study was only 4 months. Thus, these data cannot address long-term safety of canakinumab, nor effects on glucose or insulin resistance with longer-term therapy.
Second, several methods can reduce IL-1 activity, including inhibition of the IL-1 receptor, which may lead to differential physiological effects. In a study of the IL-1 receptor antagonist anakinra in a less well-controlled (HbA1c baseline 8.7%) diabetic population, HbA1c levels fell significantly, although the magnitude of this effect was modest. 27 Unlike canakinumab, anakinra also inhibits IL-1␣ signaling. Whether the more specific inhibition of IL-1␤ afforded by canakinumab as compared with anakinra has a net clinical benefit is uncertain and cannot be addressed in the present trial. Furthermore, the current phase II trial cannot address the question of whether canakinumab would have impacted diabetic glucose control parameters significantly in a less well-controlled diabetic population like the one studied in the anakinra trial or in a setting with prolonged treatment beyond the 4-month period observed here.
Third, despite enrolling a population widely considered to have a coronary heart disease risk equivalent, not all of our study participants were taking a statin. Our sensitivity analyses, however, show that canakinumab was effective at reducing CRP, IL-6, and fibrinogen among those who were and were not taking statin therapy.
Recent genetic analyses have raised the hypothesis that IL-6 signaling may have a potential role in atherothrombosis 28, 29 and, thus, the current data describing dose-dependent effects on IL-6 (and on the downstream biomarkers CRP and fibrinongen) have interest for the cardiovascular prevention community. Alternative explanations for these data exist, however, and only a large-scale hard outcomes trial can answer broader questions about inflammation inhibition. Indeed, the results of this phase IIb trial, as well as other phase II safety evidence evaluating canakinumab in the settings of rheumatoid arthritis and gout, provided crucial pathophysiologic support, as well as dose-finding data allowing us to design and initiate a large-scale hard outcomes trial of canakinumab in the secondary prevention of cardiovascular events. That trial, the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), 30 is now enrolling patients in Ͼ35 countries and addresses directly the potential for canakinumab to reduce incident cardiovascular events in a secondary prevention population with a persistent proinflammatory response. CANTOS will randomly allocate Յ17 200 patients with CRP Ͼ2 mg/L to placebo or to canakinumab, with all of the participants followed prospectively over an estimated 4-year period for the trial primary end point (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death), as well as for other vascular events, total mortality, and selected clinical end points associated with inflammation, such as new-onset diabetes mellitus, diabetes progression, venous thromboembolism, congestive Units for IL-6 are nanograms per liter. The last observation carried forward was used for patients without a 4-mo sample for any reason. P values for the total group are calculated from an ANCOVA of the change from baseline in log IL-6 with treatment and metformin dose group as main effects and baseline IL-6 as a covariate. P values for the sex-stratified groups are calculated from an ANCOVA of the change from baseline in log IL-6 with treatment and metformin dose group as main effects and baseline IL-6 and sex as covariates including interaction terms treatment*gender, treatment*baseline IL-6, and gender*baseline IL-6. IQR indicates interquartile range; IL-6, interleukin-6.
heart failure, and atrial fibrillation. Because the CANTOS entry criteria include an elevated CRP despite concurrent statin therapy, many CANTOS participants should have insulin resistance, obesity, or frank diabetes mellitus, mimicking the population studied here.
In addition to its potential role in atherothrombosis, IL-1 signaling participates in innate immune regulation within diverse organ systems and has effects on multiple cell types, including endothelial cells, fibroblasts, macrophages, lymphocytes, osteoclasts, and chondrocytes. To date, studies of canakinumab in the setting of rheumatoid arthritis, diabetes mellitus, and gout have not shown significant hazard associated with these effects, although a modest increase in infection has been seen. Nonetheless, systemic infection, incident Units for fibrinogen are grams per liter. The last observation carried forward was used for patients without a 4-mo sample for any reason. P values for the total group are calculated from an ANCOVA of the change from baseline in log fibrinogen with treatment and metformin dose group as main effects and baseline fibrinogen as a covariate. P values for the sex-stratified groups are calculated from an ANCOVA of the change from baseline in log fibrinogen with treatment and metformin dose group as main effects and baseline fibrinogen and sex as covariates including interaction terms treatment*gender, treatment*baseline fibrinogen, and gender*baseline fibrinogen. IQR indicates interquartile range. cancers, and potential adverse effects on renal, pulmonary, and hepatic function are all being carefully followed in the ongoing phase III CANTOS clinical trial. Furthermore, given the significant 10% increase in triglycerides observed in these data at the 2 higher doses of canakinumab, monitoring for elevated triglycerides is being conducted for all of the CANTOS participants, because recent evidence suggests that such elevations are an independent marker for elevated vascular risk. Absolute neutrophil counts are also being monitored in the CANTOS trial.
In sum, the phase IIb data presented here provide a firm foundation in humans for the use of canakinumab as one approach to test whether therapeutic targeting of inflammation can reduce the residual burden of recurrent events in patients on current standard of care treatment after myocardial infarction.
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